Year: 2024
Type: article
Abstract: INTRODUCTION The relationship between cerebrovascular disease (CVD) and amyloid beta (Aβ) in Alzheimer's disease (AD) is understudied. We hypothesized that magnetic resonance imaging (MRI)–based CVD biomarkers—including cerebral microbleeds (CMBs), lacunar infarction, and white matter hyperintensities (WMHs)—would correlate with Aβ positivity on positron emission tomography (Aβ‐PET). METHODS We cross‐sectionally analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI, N = 1352). Logistic regression was used to calculate odds ratios (ORs), with Aβ‐PET positivity as the standard‐of‐truth. RESULTS Following adjustment, WMHs (OR = 1.25) and superficial CMBs (OR = 1.45) remained positively associated with Aβ‐PET positivity (p < 0.001). Deep CMBs and lacunes exhibited a varied relationship with Aβ‐PET in cognitive subgroups. The combined diagnostic model, which included CVD biomarkers and other accessible measures, significantly predicted Aβ‐PET (pseudo‐R2 = 0.41). DISCUSSION The study highlights the translational value of CVD biomarkers in diagnosing AD, and underscores the need for more research on their inclusion in diagnostic criteria. ClinicalTrials.gov: ADNI‐2 (NCT01231971), ADNI‐3 (NCT02854033). Highlights Cerebrovascular biomarkers linked to amyloid beta (Aβ) in Alzheimer's disease (AD). White matter hyperintensities and cerebral microbleeds reliably predict Aβ‐PET positivity. Relationships with Aβ‐PET vary by cognitive stage. Novel accessible model predicts Aβ‐PET status. Study supports multimodal diagnostic approaches.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.14207
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,000
Funders: U.S. Department of Defense, Alzheimer's Association, Bristol-Myers Squibb, Alzheimer's Drug Discovery Foundation, Eli Lilly and Company, Roche, Biogen, BioClinica, Novartis Pharmaceuticals Corporation, Takeda Pharmaceutical Company, Fujirebio US, Servier, National Institutes of Health, Genentech, GE Healthcare, Canadian Institutes of Health Research, National Institute on Aging, National Institute of Mental Health, National Institute of Biomedical Imaging and Bioengineering
Awards: G100845555, G104586243, G1650819308, Promoting Research Training During Psychiatry Residency, G2105457377, G2189010064, G2340207221, G3146424788, G3512028809, Neuroanatomical associations with the factor structure underlying neuropsychiatric symptoms in Alzheimer's disease, G4119534169, G4475667458, G4800177743, G5207404921, EFFECTS OF TRAUMATIC BRAIN INJURY (TBI) AND POST TRAUMATIC STRESS DISORDER (PTSD) ON ALZHEIMER'S DISEASE (AD) IN VETERANS USING IMAGING AND BIOMARKERS IN THE AD NEUROIMAGING INITIATIVE (ADNI)", G5654639750, Alzheimer's Disease Neuroimaging Initiative, G5850682332, G6210868510, G6371410416, Using RDoC Negative and Positive Valence Paradigms to Investigate the Mechanisms of Neuropsychiatric Symptoms (NPS) in Alzheimer's Disease and Related Dementias, G764699806, Developing novel cognitive and neuroimaging markers of early Alzheimers disease pathologies, G8228018387, G8895907669, G9000039018, G9000122335, Genetic and neuroanatomical basis of neuropsychiatric symptoms in Alzheimer's disease in populations of diverse ancestry, Role of Retrotransposon Activity in Neurodegeneration and Alzheimer's Disease
OpenAlex ID: W4402139978